- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Weight Loss
Recent news which mentions Weight Loss
Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder
April 07, 2025
From Benzinga
Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales
April 02, 2025
From Benzinga
Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight
March 31, 2025
From Benzinga
From Benzinga
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk
March 28, 2025
From Benzinga
EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing
March 26, 2025
From Benzinga
From Benzinga
UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk's Membership After 2 Years Of Suspension
March 17, 2025
From Benzinga
CVS Weight Management Program Yields 15% Average Weight Loss, 26% Cost Saving Among Participants
March 14, 2025
From Benzinga
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders
March 14, 2025
From Benzinga
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
March 13, 2025
From Benzinga
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs
March 12, 2025
From Benzinga
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
March 11, 2025
From Benzinga
Weight Loss Drugs Soar While Global Obesity Rates Climb, To Hit 50% Of Adults By 2050 Says New Report
March 06, 2025
From Benzinga
Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss
March 06, 2025
From Benzinga
Why Is Hims & Hers Health Stock Trading Lower On Wednesday?
March 05, 2025
From Benzinga
From Benzinga
From Benzinga
Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision
February 26, 2025
From Benzinga
From Benzinga
What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?
February 05, 2025
From Benzinga
Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026
February 05, 2025
From Benzinga
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
February 04, 2025
From Benzinga
From Benzinga
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
January 24, 2025
From Benzinga
Revolutionising Non-Surgical Fat Loss
January 13, 2025
From PRLog
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
January 06, 2025
From Benzinga
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
December 20, 2024
From Benzinga
From Benzinga
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
November 26, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.